COMMUNIQUÉS West-GlobeNewswire

Imprivata Recognized in Constellation ShortList™ for Healthcare IT Security
19/08/2026
Recognition highlights Imprivata's leadership in helping healthcare delivery organizations strengthen security while delivering fast, frictionless access to devices, applications, and other critical systems WALTHAM, [...]
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
19/08/2026
-- Modular PMA pathway advances FemBloc toward potential U.S. approval while Femasys builds commercial infrastructure across its reproductive health portfolio -- ATLANTA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. ( [...]
InterCure Ltd. Announces 1-for-5 Reverse Share Split
19/08/2026
Strategic Action Aimed at Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Protecting Continued Listing Status NEW YORK and HERTZLIYA, ISRAEL, Aug. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (the “ [...]
Regional Health Properties Reports Second Quarter 2026 Results
19/08/2026
.Reported Second Quarter Revenue of $24.4 million Generated Adjusted EBITDA from Operations of $0.7 million Continued Execution of Integrated Healthcare Platform Strategy ATLANTA, GA, Aug. 19, 2026 (GLOBE NEWSWIRE) -- [...]
Earth Science Tech, Inc. (ETST) Acquires Zoolzy LLC to Drive Margin Expansion and Strategic Entry into the Veterinary Market
19/08/2026
MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Zoolzy LLC, a [...]
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
19/08/2026
August 19, 2026 Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP 87 subjects, over 50% of target, recruited Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a [...]
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
19/08/2026
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b [...]
NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System
19/08/2026
Certified Traveler system supports resilient power deployment for Missanabie Cree First Nation in Northern Ontario, Canada BOCA RATON, Fla., Aug. 19, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions Inc. ("NOMAD" or the " [...]
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth
19/08/2026
Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active [...]
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
19/08/2026
Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with [...]
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
19/08/2026
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
19/08/2026
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary [...]
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
19/08/2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
19/08/2026
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data [...]
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
19/08/2026
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy pipeline toward commercialization DURHAM, N.C., Aug [...]
Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea
19/08/2026
Global milestone reflects sustained physician utilization, patient adoption and the expanding reach of Sofwave’s SUPERB™ technology SAN CLEMENTE, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: [...]
Applied Biologics Welcomes CMS’ Continued Commitment to Clinical Evidence in Advanced Wound Care
19/08/2026
Applied Biologics believes continued investment in high-quality clinical research is essential to advancing patient care SCOTTSDALE, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical [...]
SK pharmteco célèbre l’avancement des travaux par une cérémonie d’inauguration de deux sites de production de pointe sur son campus de Swords, en Irlande
19/08/2026
L’événement souligne une importante augmentation de la capacité de production commerciale d’API de petites molécules et l’ouverture d’une nouvelle unité de production à l’échelle du kilogramme, conforme aux BPF, dédiée [...]
Avicanna Announces Closing of Strategic Non-Brokered Private Placement
19/08/2026
Strategic investment by pharmaceutical executive and life sciences investor Michael Porter TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a [...]

Pages